Komori
M&A and Subsidiary Changes6190PhoenixBio Co.,Ltd.Information and communications, services and other

(Progress on Previously Disclosed Matter) Notice of Completion of Liquidation of a Consolidated Subsidiary

The liquidation procedures for CMHL Consortium LLC, a consolidated subsidiary, have been completed, and the completion of the liquidation was confirmed on 16 November 2026 (17 November 2026 Japan time).

Worth reading
19Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

This transaction

Liquidation of a Consolidated Subsidiary
Disclosing companyPhoenixBio Co.,Ltd.
CMHL Consortium LLCSubject of this transactionVoting rights ownership percentage Before 100% (after not disclosed)
Execution Date / Effective Date16 November 2026 local time (17 November 2026 Japan time)
Target company

Management of a consortium for research into the utility of PXB mice

Location Delaware, United StatesShare capital US$250,000Date of incorporation January 2016
Impact on Business Performance

The impact of the completion of the liquidation of the company on consolidated results is immaterial.

This transaction
ItemDetails
Transaction nameLiquidation of a Consolidated Subsidiary
Name of the Subject CompanyCMHL Consortium LLC
Business Description of the Subject CompanyManagement of a consortium for research into the utility of PXB mice
Location of the Subject CompanyDelaware, United States
Capital Stock of the Subject CompanyUS$250,000
Date of Establishment of the Subject CompanyJanuary 2016
Voting rights ownership percentageBefore 100% (after not disclosed)
Impact on Business PerformanceThe impact of the completion of the liquidation of the company on consolidated results is immaterial.
Execution Date / Effective Date16 November 2026 local time (17 November 2026 Japan time)
Items this document does not state (23)
Counterparty nameNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This disclosure does not explain the reason for the liquidation.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Progress on Previously Disclosed Matter) Notice of Completion of Liquidation of a Consolidated Subsidiary | PhoenixBio Co.,Ltd. (6190) timely disclosure | Komori